Antipsychotic Drugs

Antipsychotic Drugs Market Outlook

The global antipsychotic drugs market is poised to reach an estimated value of USD 18.6 billion by 2026, growing at a compound annual growth rate (CAGR) of approximately 4.6% from 2021 to 2026. This growth is being propelled by several factors, including a rising prevalence of mental health disorders such as schizophrenia and bipolar disorder, increasing awareness about mental health, and improved healthcare access globally. Additionally, advancements in drug formulations that enhance patient compliance and reduce side effects are also contributing to market growth. The growing geriatric population, which is highly susceptible to dementia-related disorders, further intensifies the demand for effective antipsychotic treatments. Moreover, the increasing focus on innovative drug development and personalized medicine is expected to revolutionize treatment modalities in this sector.

Growth Factor of the Market

One of the primary growth factors affecting the antipsychotic drugs market is the increase in mental health disorders globally, particularly among the adult and geriatric populations. The World Health Organization (WHO) estimates that around 1 in 4 individuals will experience a mental health issue at some point in their lives, creating a surge in demand for antipsychotic medications. Furthermore, the stigma surrounding mental health has begun to dissipate, leading to higher diagnosis rates and subsequent treatment prescriptions. Alongside this, the advent of telemedicine has expanded access to psychiatric care, allowing more patients to receive appropriate prescriptions for antipsychotic drugs. The ongoing research and development efforts are also noteworthy, as new formulations aim to address the challenges of adherence and efficacy in treating complex mental health conditions. This holistic approach to managing mental health signifies a promising trajectory for the antipsychotic drugs market, ensuring it remains a vital sector within the pharmaceutical industry.

Key Highlights of the Market

• The global antipsychotic drugs market is projected to grow at a CAGR of 4.6% from 2021 to 2026.
• Increasing prevalence of mental health disorders, especially among the elderly, is driving demand.
• Innovations in drug formulations and delivery mechanisms are enhancing patient compliance.
• Growing awareness about mental health and telemedicine are improving access to treatment.
• Emerging markets in Asia Pacific and Latin America present new growth opportunities.

By Product Type

Typical Antipsychotic Drugs :

Typical antipsychotic drugs, also known as first-generation antipsychotics, have been in use for several decades and are primarily effective in treating positive symptoms of schizophrenia, such as hallucinations and delusions. Medications such as Haloperidol and Chlorpromazine fall under this category. Despite being effective, these drugs are often associated with a higher incidence of side effects, including extrapyramidal symptoms, which can discourage patients from adhering to their treatment regimens. Nevertheless, typical antipsychotics still hold a significant market share due to their established efficacy, affordability, and availability. As healthcare providers become more adept at managing side effects, typical antipsychotic medications continue to be prescribed, particularly in acute care settings, resulting in steady demand in the antipsychotic drugs market.

Atypical Antipsychotic Drugs :

Atypical antipsychotic drugs, or second-generation antipsychotics, have gained popularity over traditional medications due to their more favorable side effect profiles and effectiveness in treating both positive and negative symptoms of schizophrenia. Drugs such as Risperidone, Quetiapine, and Olanzapine fall into this category, and they are often preferred for their lower risk of causing extrapyramidal symptoms. This has led to a substantial market share for atypical antipsychotics, as they are frequently prescribed in outpatient settings for both schizophrenia and bipolar disorder. The ongoing research into novel atypical antipsychotics continues to attract interest, as pharmaceutical companies aim to develop medications that minimize side effects further while maximizing therapeutic effects, ensuring this segment remains robust in the market.

Others :

This category encompasses a range of antipsychotic medications that do not fit neatly into typical or atypical classifications. These can include newer classes of drugs or those that are still undergoing clinical trials. The segment is characterized by innovations aimed at addressing various aspects of mental health conditions, including treatment-resistant cases. Though currently a smaller segment of the market, 'others' is anticipated to grow as pharmaceutical advancements are made and as the understanding of psychiatric conditions evolves. The potential for these novel therapies to make a significant impact on treatment options enhances the overall growth potential of the antipsychotic drugs market.

By Application

Schizophrenia :

Schizophrenia is one of the most significant applications within the antipsychotic drugs market, as it is a severe mental disorder affecting millions worldwide. The need for effective management of this condition drives demand for antipsychotic medications, both typical and atypical. Schizophrenia's complex symptomatology necessitates long-term treatment strategies, supported by ongoing medication adherence and regular psychiatric evaluations. Recent advancements in drug formulation aim to improve patients’ quality of life by reducing side effects and enhancing overall treatment outcomes. As awareness of mental health issues continues to grow, the focus on effective treatments for schizophrenia will likely sustain this segment's momentum.

Bipolar Disorder :

Bipolar disorder, characterized by episodes of depression and mania, constitutes another critical application for antipsychotic medications. Atypical antipsychotics are commonly utilized in treating the manic phases of bipolar disorder and as adjuncts to mood stabilizers. The increasing diagnosis rates, combined with the rising acceptance of pharmacotherapy for managing this condition, has propelled the bipolar disorder segment's growth within the antipsychotic drugs market. Continuous research into the efficacy of various antipsychotic medications is driving further exploration into tailored treatment strategies that address the unique needs of individuals with bipolar disorder.

Depression :

Antipsychotic medications are also gaining traction in the treatment of depression, particularly in cases of treatment-resistant depression. The use of atypical antipsychotics as adjunctive therapy to traditional antidepressants can provide relief for patients who do not respond adequately to standard treatments. This application is particularly relevant as mental health awareness grows and more patients seek comprehensive solutions to manage their symptoms. As ongoing research continues to explore the efficacy of combining antipsychotic medications with conventional antidepressants, this segment of the market is expected to experience notable growth in the coming years.

Dementia :

Dementia-associated behavioral disturbances often necessitate the use of antipsychotic drugs to manage symptoms such as agitation and psychosis. Despite the controversy surrounding the use of these drugs in elderly populations due to associated risks, the demand for effective management options remains high. Pharmaceutical companies are increasingly focusing on developing safer alternatives that minimize adverse effects while still effectively addressing dementia-related symptoms. As the global population ages and the prevalence of dementia escalates, this application segment of antipsychotic drugs is anticipated to expand significantly.

Others :

This segment includes various other applications that utilize antipsychotic medications, such as post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), and other psychiatric conditions. The growing recognition of these disorders and the potential for antipsychotic drugs in managing symptoms is enhancing the market's diversity. As ongoing research uncovers new therapeutic applications and combinations, this 'others' segment is expected to gain traction, further enriching the overall landscape of the antipsychotic drugs market.

By Distribution Channel

Hospital Pharmacies :

Hospital pharmacies play a significant role in the distribution of antipsychotic drugs, given their central role in inpatient care and psychiatric treatment facilities. These pharmacies are essential for providing timely and effective treatment options to patients admitted for acute psychiatric episodes. The ability of hospital pharmacies to offer a comprehensive selection of antipsychotic medications is crucial for healthcare providers in managing complex cases. Furthermore, the presence of clinical pharmacists within hospitals enhances the integration of pharmacotherapy into patient care, ensuring proper medication management and adherence, which ultimately supports the overall growth of this distribution channel.

Retail Pharmacies :

Retail pharmacies are a critical component of the antipsychotic drugs distribution network, as they provide access to medications for outpatient care and ongoing treatment management. The convenience and accessibility of retail pharmacies make them a preferred choice for many patients who require regular refills and consultations. Furthermore, retail pharmacies are increasingly integrating mental health services into their offerings, such as counseling and medication therapy management. This trend is expected to bolster the retail pharmacy segment significantly, as patients become more empowered to seek support for their mental health needs. The strong presence of retail pharmacies ensures that antipsychotic drugs remain readily available to those who need them.

Online Pharmacies :

The rise of online pharmacies has transformed the distribution landscape of antipsychotic drugs, providing patients with an alternative means of obtaining their medications. The convenience of online ordering, coupled with discreet delivery options, appeals to individuals seeking to manage sensitive health conditions like mental disorders. Furthermore, the COVID-19 pandemic accelerated the adoption of online pharmacy services, as many patients preferred to limit in-person visits. This trend has prompted both traditional pharmacy chains and new entrants to develop robust online platforms, enhancing the overall market reach of antipsychotic medications. As technology continues to evolve, the online pharmacy segment is anticipated to grow, offering patients more accessible options for managing their mental health.

By Ingredient Type

Risperidone :

Risperidone is one of the leading ingredients in the antipsychotic drugs market, primarily used for treating schizophrenia, bipolar disorder, and irritability associated with autism. This atypical antipsychotic has gained considerable acceptance due to its efficacy in managing both positive and negative symptoms with a relatively favorable side effect profile. The drug’s versatility makes it a preferred choice among healthcare providers, and it is often included in treatment regimens for diverse psychiatric conditions. Continuous research into the long-term effects and potential new applications for Risperidone ensures its sustained relevance in the antipsychotic drugs market.

Olanzapine :

Olanzapine has proven to be an important player within the antipsychotic drugs market, particularly for its effectiveness in treating schizophrenia and acute manic episodes of bipolar disorder. Its broad efficacy and established safety profile have made it a staple in psychiatric treatment. Olanzapine’s ability to address both positive and negative symptoms has bolstered its use in various patient populations, contributing to its strong market presence. Ongoing studies are exploring the potential benefits and risks associated with long-term use, ensuring that Olanzapine remains a significant focus within pharmaceutical development and clinical practice.

Quetiapine :

Quetiapine is another widely prescribed atypical antipsychotic known for its flexibility in treating a range of psychiatric conditions, including schizophrenia, bipolar disorder, and major depressive disorder as an adjunct treatment. Its unique pharmacological profile allows it to effectively manage mood stabilization while minimizing side effects, which is particularly appealing to both patients and healthcare providers. The ongoing research into Quetiapine’s diverse therapeutic applications and its favorable tolerability profile solidify its position as a leading ingredient in the antipsychotic drugs market, ensuring it remains integral to treatment regimens for various mental health disorders.

Aripiprazole :

Aripiprazole is regarded as a groundbreaking atypical antipsychotic, offering a distinct mechanism of action that makes it effective in treating schizophrenia and bipolar disorder while exhibiting a lower risk of side effects such as sedation and weight gain. Its unique properties have led to its adoption in diverse treatment scenarios, including use for pediatric populations and as adjunct therapy for depression. The growing body of evidence supporting Aripiprazole's effectiveness and safety has expanded its market presence, with ongoing research aimed at uncovering additional therapeutic applications. As mental health awareness increases, the demand for Aripiprazole is expected to rise, solidifying its importance within the antipsychotic drug landscape.

Others :

This segment encompasses a variety of additional ingredients contributing to the antipsychotic drugs market, including lesser-known atypical antipsychotics and new chemical entities currently undergoing clinical trials. The growing exploration of alternative pharmacological options aims to address the limitations and side effects associated with established antipsychotic medications. This area is particularly dynamic, as innovations in drug discovery and development continue to emerge. The successful introduction of novel agents will not only enhance treatment options for patients but also add complexity and depth to the overall antipsychotic drugs market.

By Region

The North American region holds the largest share of the global antipsychotic drugs market, driven by a high prevalence of mental health disorders, robust healthcare infrastructure, and extensive research and development initiatives. In 2021, North America accounted for approximately 40% of the market share, with the United States being the largest contributor. The increasing acceptance of mental health treatments, together with the availability of a wide array of antipsychotic medications, has solidified the region's dominance. Furthermore, the growing utilization of telepsychiatry services and mental health awareness campaigns have significantly enhanced patient access to care, ensuring sustained market growth. Analysts project that the North American antipsychotic drugs market will continue to grow at a CAGR of 4.0% from 2021 to 2026.

Europe occupies a significant position in the antipsychotic drugs market, contributing approximately 30% to the global market share. The rising mental health issues, combined with an aging population susceptible to dementia and other mental disorders, are key drivers of growth in this region. European countries are increasingly prioritizing mental health in public health agendas, which translates into better funding for research and improved access to treatments. Additionally, the regulatory landscape in Europe is conducive to drug innovation, fostering the development of new antipsychotic medications. The Asia Pacific region is anticipated to demonstrate the fastest growth, with a projected CAGR of 5.5%, as increasing urbanization and changing lifestyle patterns contribute to a rising prevalence of mental health disorders in developing countries. This growth highlights the need for effective mental health treatment solutions, making it a crucial area for pharmaceutical investment. The Latin America and Middle East & Africa regions, while currently smaller markets, are also expected to witness growth driven by increased awareness and gradual improvements in healthcare access.

Opportunities

The antipsychotic drugs market is rife with opportunities for growth, particularly in emerging markets where mental health awareness is gaining traction. Countries in regions such as Asia Pacific and Latin America are witnessing an increase in healthcare spending, coupled with a rising focus on addressing mental health needs. This creates a fertile ground for pharmaceutical companies to introduce new products tailored to meet local demands. Additionally, the development of digital health solutions, such as telemedicine and mental health apps, provides an avenue for improving patient access to antipsychotic medications. As healthcare systems evolve to incorporate these technologies, the market's reach can significantly expand, leading to enhanced treatment adherence and better patient outcomes.

Another opportunity lies in the innovation of drug delivery systems designed to improve patient adherence and reduce the burden of side effects. Extended-release formulations and long-acting injectable antipsychotics are gaining attention as they offer patients a more manageable approach to their treatment regimens. As healthcare providers increasingly recognize the importance of adherence in achieving successful outcomes, the demand for these advanced formulations is expected to grow. Furthermore, public initiatives aimed at de-stigmatizing mental health care can drive demand for antipsychotic medications, encouraging more individuals to seek treatment and ultimately benefiting the overall market.

Threats

Despite the promising growth trajectory of the antipsychotic drugs market, several threats loom on the horizon. One significant concern is the increasing scrutiny surrounding the use of antipsychotic medications, especially in vulnerable populations such as the elderly. Regulatory agencies are placing greater emphasis on the safety and efficacy of these drugs, which may lead to stricter guidelines and reduced prescribing practices. Additionally, the potential for adverse effects, including metabolic syndrome and other long-term health issues, remains a significant concern for both patients and providers. Such challenges may result in higher regulatory barriers and increased pressure to develop safer alternatives, complicating market dynamics.

Another critical threat involves the growing competition from alternative therapies, including psychotherapy and holistic approaches to mental health treatment. As patients and healthcare providers seek comprehensive care options, there is a risk of traditional antipsychotic medications being overshadowed by these emerging therapies. Furthermore, the potential for generic versions of established antipsychotic drugs entering the market could lead to price erosion and decreased revenues for branded medications. As the landscape of mental health treatment continues to evolve, the antipsychotic drugs market must adapt to these changing dynamics to maintain its relevance and competitiveness.

Competitor Outlook

• Johnson & Johnson
• Eli Lilly and Company
• Pfizer Inc.
• Roche Holding AG
• GlaxoSmithKline plc
• AstraZeneca PLC
• Otsuka Pharmaceutical Co., Ltd.
• Sanofi S.A.
• Novartis AG
• Merck & Co., Inc.
• H Lundbeck A/S
• Teva Pharmaceutical Industries Ltd.
• Akorn, Inc.
• Allergan plc
• Boehringer Ingelheim GmbH

The competitive landscape of the antipsychotic drugs market is characterized by a diverse array of players, ranging from well-established pharmaceutical giants to emerging biotech firms. Leading companies like Johnson & Johnson and Eli Lilly dominate the market, leveraging their vast resources to invest in research and development initiatives aimed at discovering innovative treatments for mental health disorders. These companies possess extensive portfolios of antipsychotic medications, ensuring they remain at the forefront of the market. Additionally, strategic partnerships and collaborations with research institutions and healthcare providers have enabled these firms to stay ahead of the curve, allowing them to quickly adapt to changes in market demands and regulatory landscapes.

Moreover, emerging players are entering the market with a focus on novel drug formulations and delivery methods, seeking to carve out niches by addressing unmet medical needs. Startups and biotechnology firms are increasingly developing specialized antipsychotic medications that target specific patient populations or optimize treatment efficacy. This trend towards innovation is reshaping the competitive landscape, prompting established players to reassess their strategies and consider acquisitions and collaborations to enhance their product offerings. As the market continues to evolve, the competition is expected to intensify, emphasizing the need for ongoing investment in drug development and a keen awareness of emerging trends.

In terms of key competitors, Otsuka Pharmaceutical stands out with its flagship product, Aripiprazole, which has carved a significant share of the market due to its unique mechanism of action and favorable side effect profile. The company has been proactive in expanding its indications, allowing for broader utilization across various psychiatric conditions. Additionally, AstraZeneca and Pfizer are also notable players, recognized for their commitment to research and development, particularly in the field of mental health. Their extensive pipelines and strategic focus on enhancing patient outcomes position them as formidable competitors in the antipsychotic drugs market. This competitive landscape underscores the importance of innovation, adaptability, and patient-centered approaches in maintaining a strong market presence.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Akorn, Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Novartis AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Sanofi S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Allergan plc
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 H Lundbeck A/S
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 AstraZeneca PLC
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Roche Holding AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Johnson & Johnson
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Merck & Co., Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 GlaxoSmithKline plc
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Eli Lilly and Company
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Boehringer Ingelheim GmbH
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Otsuka Pharmaceutical Co., Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Antipsychotic Drugs Market, By Application
    • 6.1.1 Schizophrenia
    • 6.1.2 Bipolar Disorder
    • 6.1.3 Depression
    • 6.1.4 Dementia
    • 6.1.5 Others
  • 6.2 Antipsychotic Drugs Market, By Product Type
    • 6.2.1 Typical Antipsychotic Drugs
    • 6.2.2 Atypical Antipsychotic Drugs
    • 6.2.3 Others
  • 6.3 Antipsychotic Drugs Market, By Ingredient Type
    • 6.3.1 Risperidone
    • 6.3.2 Olanzapine
    • 6.3.3 Quetiapine
    • 6.3.4 Aripiprazole
    • 6.3.5 Others
  • 6.4 Antipsychotic Drugs Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Antipsychotic Drugs Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Antipsychotic Drugs market is categorized based on

By Product Type

• Typical Antipsychotic Drugs
• Atypical Antipsychotic Drugs
• Others

By Application

• Schizophrenia
• Bipolar Disorder
• Depression
• Dementia
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Risperidone
• Olanzapine
• Quetiapine
• Aripiprazole
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Johnson & Johnson
• Eli Lilly and Company
• Pfizer Inc.
• Roche Holding AG
• GlaxoSmithKline plc
• AstraZeneca PLC
• Otsuka Pharmaceutical Co., Ltd.
• Sanofi S.A.
• Novartis AG
• Merck & Co., Inc.
• H Lundbeck A/S
• Teva Pharmaceutical Industries Ltd.
• Akorn, Inc.
• Allergan plc
• Boehringer Ingelheim GmbH